SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Zydus Pharmaceuticals Ltd. - (Amalgamated)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Zydus Pharmaceutical Share Price

BSE Share Price
Not Listed

Zydus Pharmaceuticals Ltd. - (Amalgamated)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Zydus Pharmaceutical Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹0 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹0
TTM Sales
₹0 Cr.
Book Value per Share
-
P/E Ratio
0.00
Industry PE
46.6
Price to Book (P/B)
0.00
Price to Sales (P/S)
0.00
EV/EBITDA
0.00
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
7.10%
Return on Capital Employed (ROCE)
19.97%
Return on Assets (ROA)
12.55%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
50%
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
-
Equity
₹0 Cr.
Face Value
₹10
All Time Low / High
- / -

Zydus Pharmaceuticals . - (Amalgamated) stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation ⓘ

Mar'10Mar'11Mar'12TTM
ROCE % ⓘ10%6.7%20%-

Growth Parameters ⓘ
Sales ⓘ0000
Sales YoY Gr.-NANA-
Adj EPS ⓘ1.20.81.30
YoY Gr.--31%58.8%-
BVPS (₹) ⓘ17.417.600
Adj Net
Profit ⓘ		0.10.10.10
Cash Flow from Ops. ⓘ1.1-0.10-
Debt/CF from Ops. ⓘ000-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANANANA
Adj EPS ⓘNANANA58.8%
BVPSⓘNANANA-100%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'10Mar'11Mar'12TTM
Return on
Equity % ⓘ		6.74.614.5NAN
Op. Profit
Mgn % ⓘ		000NAN
Net Profit
Mgn % ⓘ		000NAN
Debt to
Equity ⓘ		000-
Working Cap
Days ⓘ		0000
Cash Conv.
Cycle ⓘ		0000

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'10Mar'11Mar'12
Sales000
Operating Expenses ⓘ + 0.030.010
Manufacturing Costs000
Material Costs000
Employee Cost 000
Other Costs ⓘ 0.030.010
Operating Profit ⓘ -0.03-0.01-0
Operating Profit Margin (%) ---
Other Income ⓘ + 0.190.120.17
Exceptional Items ⓘ 000
Interest ⓘ 000
Depreciation ⓘ 000
Profit Before Tax ⓘ 0.160.110.17
Tax ⓘ 0.060.030.05
Profit After Tax 0.110.080.12
PAT Margin (%) ---
Adjusted EPS (₹)1.10.80.0
Dividend Payout Ratio (%)446.90%62.50%0%

Valuation of Zydus Pharmaceutical - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'10Mar'11Mar'12

Equity and Liabilities

Shareholders Fund + 1.651.671.73
Share Capital ⓘ 0.950.950.95
Reserves ⓘ 0.700.720.78
Debt +000
Long Term Debt000
Short Term Debt000
Minority Interest000
Trade Payables0.060.060
Others Liabilities ⓘ 0.700.20-1.73
Total Liabilities ⓘ 2.411.930

Fixed Assets

Net Fixed Assets ⓘ +0.060.060.06
Gross Block0.080.080.06
Accumulated Depreciation0.020.020
CWIP ⓘ 000
Investments ⓘ 0.090.090
Inventories000
Trade Receivables000.05
Cash Equivalents flag ⓘ 2.141.651.78
Others Assets ⓘ 0.110.12-1.89
Total Assets ⓘ 2.411.930

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'10Mar'11
Cash Flow From Operating Activity ⓘ + 1.13-0.05
PBT ⓘ 0.160.11
Adjustment ⓘ -0.19-0.12
Changes in Working Capital ⓘ 1.21-0.01
Tax Paid ⓘ -0.06-0.03
Cash Flow From Investing Activity ⓘ + 0.180.11
Capex 00
Net Investments 00
Others ⓘ 0.180.11
Cash Flow From Financing Activity ⓘ + 0-0.55
Net Proceeds from Shares ⓘ 00
Net Proceeds from Borrowing ⓘ 00
Interest Paid ⓘ 00
Dividend Paid ⓘ 0-0.48
Others ⓘ 0-0.08
Net Cash Flow ⓘ 1.31-0.49

Financial Ratio

PARTICULARSMar'10Mar'11Mar'12
Ratios
ROE (%)6.454.587.1
ROCE (%)9.986.6719.97
Asset Turnover Ratio000
PAT to CFO Conversion(x)10.27-0.630
Working Capital Days
Receivable Days000
Inventory Days000
Payable Days000

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Zydus Pharmaceuticals Ltd. - (Amalgamated) FAQs

The current trading price of Zydus Pharmaceutical on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Zydus Pharmaceutical stood at ₹0.00 Cr

The latest P/E ratio of Zydus Pharmaceutical as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Zydus Pharmaceutical as of 31-Dec-1969 is 0.00.

The 52-week high of Zydus Pharmaceutical is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zydus Pharmaceutical is ₹0.00 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Zydus Pharmaceuticals Ltd. - (Amalgamated)

No data to display
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×